JP7398448B2 - ヒト免疫不全ウイルス複製の阻害剤 - Google Patents

ヒト免疫不全ウイルス複製の阻害剤 Download PDF

Info

Publication number
JP7398448B2
JP7398448B2 JP2021522518A JP2021522518A JP7398448B2 JP 7398448 B2 JP7398448 B2 JP 7398448B2 JP 2021522518 A JP2021522518 A JP 2021522518A JP 2021522518 A JP2021522518 A JP 2021522518A JP 7398448 B2 JP7398448 B2 JP 7398448B2
Authority
JP
Japan
Prior art keywords
chloro
indazol
ethyl
difluoromethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021522518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505841A (ja
JP2022505841A5 (cg-RX-API-DMAC7.html
Inventor
ピー ギリス,エリック
イー. パーセラ,カイル
パテル,マノイ
エム ピース,ケヴィン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
Original Assignee
ViiV Healthcare UK No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68344933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7398448(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ViiV Healthcare UK No 5 Ltd filed Critical ViiV Healthcare UK No 5 Ltd
Publication of JP2022505841A publication Critical patent/JP2022505841A/ja
Publication of JP2022505841A5 publication Critical patent/JP2022505841A5/ja
Application granted granted Critical
Publication of JP7398448B2 publication Critical patent/JP7398448B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021522518A 2018-10-24 2019-10-22 ヒト免疫不全ウイルス複製の阻害剤 Active JP7398448B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749818P 2018-10-24 2018-10-24
US62/749,818 2018-10-24
PCT/IB2019/059020 WO2020084492A1 (en) 2018-10-24 2019-10-22 Inhibitors of human immunodeficiency virus replication

Publications (3)

Publication Number Publication Date
JP2022505841A JP2022505841A (ja) 2022-01-14
JP2022505841A5 JP2022505841A5 (cg-RX-API-DMAC7.html) 2022-10-07
JP7398448B2 true JP7398448B2 (ja) 2023-12-14

Family

ID=68344933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021522518A Active JP7398448B2 (ja) 2018-10-24 2019-10-22 ヒト免疫不全ウイルス複製の阻害剤

Country Status (25)

Country Link
US (2) US11541055B2 (cg-RX-API-DMAC7.html)
EP (1) EP3870577B1 (cg-RX-API-DMAC7.html)
JP (1) JP7398448B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210084508A (cg-RX-API-DMAC7.html)
CN (1) CN113195475A (cg-RX-API-DMAC7.html)
AR (1) AR116798A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019364739B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007362A2 (cg-RX-API-DMAC7.html)
CA (1) CA3117289A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001025A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021004679A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210207A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000062A (cg-RX-API-DMAC7.html)
EA (1) EA202190854A1 (cg-RX-API-DMAC7.html)
ES (1) ES3026145T3 (cg-RX-API-DMAC7.html)
IL (1) IL282240B2 (cg-RX-API-DMAC7.html)
MA (1) MA53973A (cg-RX-API-DMAC7.html)
MX (1) MX2021004593A (cg-RX-API-DMAC7.html)
PE (1) PE20211781A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550813A1 (cg-RX-API-DMAC7.html)
PL (1) PL3870577T3 (cg-RX-API-DMAC7.html)
PT (1) PT3870577T (cg-RX-API-DMAC7.html)
SG (1) SG11202103560YA (cg-RX-API-DMAC7.html)
TW (1) TWI824041B (cg-RX-API-DMAC7.html)
WO (1) WO2020084492A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023521460A (ja) * 2020-04-15 2023-05-24 ビーブ、ヘルスケア、ユーケー、(ナンバー5)、リミテッド ヒト免疫不全ウイルス複製の阻害剤

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
MA53973A (fr) * 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
EP3986561B1 (en) * 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
WO2021070054A1 (en) * 2019-10-08 2021-04-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US12564595B2 (en) 2019-11-28 2026-03-03 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
AU2022362855B2 (en) * 2021-10-13 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
US20250099464A1 (en) 2023-09-27 2025-03-27 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
AU2023466962A1 (en) 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504392A (ja) 2013-01-09 2016-02-12 ギリアード サイエンシーズ, インコーポレイテッド 抗レトロウイルス剤としての(ヘテロ)アリールアセトアミド誘導体
JP2017525722A (ja) 2014-08-29 2017-09-07 ギリアード サイエンシーズ, インコーポレイテッド 抗レトロウイルス剤

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037796A1 (en) 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
JP2012201642A (ja) * 2011-03-25 2012-10-22 Tsutomu Takeuchi 1−フェニルピロリジン−2,5−ジオン誘導体を有効成分とするbaffの結合阻害剤
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2016033009A1 (en) * 2014-08-27 2016-03-03 Bristol-Myers Squibb Company Imidazo[1,2-a]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication
LT3347352T (lt) 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
CA3108633A1 (en) 2018-08-09 2020-02-13 Viiv Healthcare Uk (No 5) Limited Inhibitors of human immunodeficiency virus replication
JP7361766B2 (ja) 2018-09-14 2023-10-16 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
WO2020058844A1 (en) 2018-09-20 2020-03-26 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
FR3086760A1 (fr) 2018-10-02 2020-04-03 Institut Mines Telecom Procede d'evaluation de la resistance mecanique d'un echantillon de tissu biologique
WO2020084491A1 (en) 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
MA53973A (fr) * 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
PT3870575T (pt) 2018-10-25 2023-05-12 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
ES2969030T3 (es) 2018-10-29 2024-05-16 Viiv Healthcare Uk No 5 Ltd Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana
JP2022506399A (ja) 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
US20210395248A1 (en) 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
US11429555B2 (en) 2019-02-26 2022-08-30 Apple Inc. Coprocessors with bypass optimization, variable grid architecture, and fused vector operations
EP3749105A4 (en) 2019-04-11 2021-10-06 Goli Nutrition Inc. FOOD SUPPLEMENT MADE OF APPLE CIDERED VINEGAR
US20220211704A1 (en) 2019-04-30 2022-07-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
EP3986561B1 (en) 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
EP4038068A1 (en) 2019-10-01 2022-08-10 VIIV Healthcare UK (No.5) Limited N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
ES2974657T3 (es) 2019-10-01 2024-07-01 Viiv Healthcare Uk No 5 Ltd Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana
TW202128648A (zh) 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
US12703699B2 (en) 2020-03-06 2026-08-11 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504392A (ja) 2013-01-09 2016-02-12 ギリアード サイエンシーズ, インコーポレイテッド 抗レトロウイルス剤としての(ヘテロ)アリールアセトアミド誘導体
JP2017525722A (ja) 2014-08-29 2017-09-07 ギリアード サイエンシーズ, インコーポレイテッド 抗レトロウイルス剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023521460A (ja) * 2020-04-15 2023-05-24 ビーブ、ヘルスケア、ユーケー、(ナンバー5)、リミテッド ヒト免疫不全ウイルス複製の阻害剤
JP7799620B2 (ja) 2020-04-15 2026-01-15 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤

Also Published As

Publication number Publication date
IL282240B2 (en) 2025-05-01
KR20210084508A (ko) 2021-07-07
JP2022505841A (ja) 2022-01-14
PT3870577T (pt) 2025-04-07
SG11202103560YA (en) 2021-05-28
US11541055B2 (en) 2023-01-03
PE20211781A1 (es) 2021-09-08
AU2019364739A1 (en) 2021-05-20
CO2021004679A2 (es) 2021-04-30
TWI824041B (zh) 2023-12-01
DOP2021000062A (es) 2021-09-15
WO2020084492A1 (en) 2020-04-30
CA3117289A1 (en) 2020-04-30
ES3026145T3 (en) 2025-06-10
TW202031261A (zh) 2020-09-01
IL282240A (en) 2021-05-31
PL3870577T3 (pl) 2025-06-16
US20230109662A1 (en) 2023-04-06
PH12021550813A1 (en) 2021-10-04
CL2021001025A1 (es) 2021-11-05
EP3870577B1 (en) 2025-03-19
CR20210207A (es) 2021-09-02
BR112021007362A2 (pt) 2021-07-20
EP3870577A1 (en) 2021-09-01
AU2019364739B2 (en) 2022-05-26
US20200360384A1 (en) 2020-11-19
IL282240B1 (en) 2025-01-01
MX2021004593A (es) 2021-06-15
EA202190854A1 (ru) 2021-08-17
MA53973A (fr) 2022-02-09
CN113195475A (zh) 2021-07-30
AR116798A1 (es) 2021-06-16

Similar Documents

Publication Publication Date Title
JP2022505841A (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7526174B2 (ja) キナゾリニル-インダゾール誘導体及びそのヒト免疫不全ウイルス複製の阻害剤としてのその使用
JP7500555B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7307747B2 (ja) ヒト免疫不全ウイルス複製の阻害剤としての4-オキソ-3,4-ジヒドロキナゾリン化合物
JP7433303B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7532354B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP2022551254A (ja) ヒト免疫不全ウイルスの複製阻害剤
EP4038064A1 (en) N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
US20230013823A1 (en) Inhibitors of human immunodeficiency virus replication
WO2021070054A1 (en) Inhibitors of human immunodeficiency virus replication
RU2812128C2 (ru) Ингибиторы репликации вируса иммунодефицита человека
HK40060467A (en) Inhibitors of human immunodeficiency virus replication
HK40060467B (en) Inhibitors of human immunodeficiency virus replication
EA043730B1 (ru) Ингибиторы репликации вируса иммунодефицита человека

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220929

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230928

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231204

R150 Certificate of patent or registration of utility model

Ref document number: 7398448

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350